Dual Versus Single Shock for Cardioversion of Atrial Fibrillation
NCT: NCT03943693 · TERMINATED
Brief Summary
The investigators aim to investigate the immediate success rate (rate of termination of atrial fibrillation) of dual shock cardioversion compared with standard single shock cardioversion in patients with baseline characteristics adversely influencing successful cardioversion. Baseline characteristics known to reduce the success rate of single shock cardioversion include: increased body mass index (BMI), chronic obstructive pulmonary disease, sleep apnea, enlarged left atrium, longer duration of atrial fibrillation and use of amiodarone.
Frequently Asked Questions
What is Dual Versus Single Shock for Cardioversion of Atrial Fibrillation?
Dual Versus Single Shock for Cardioversion of Atrial Fibrillation is a clinical trial registered under NCT03943693. Current status: TERMINATED.
What is the status of NCT03943693?
The current status of NCT03943693 (Dual Versus Single Shock for Cardioversion of Atrial Fibrillation) is: TERMINATED.
When did Dual Versus Single Shock for Cardioversion of Atrial Fibrillation start?
Dual Versus Single Shock for Cardioversion of Atrial Fibrillation started on 2019-04-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.